Retrospective review of docetaxel, cisplatin, and 5FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer

15525 Background: DCF administered every three weeks results in a high rate of treatment-related adverse events. At M.D. Anderson Cancer Center (MDACC) a weekly formulation of DCF has been utilized...